BioAtla, LLC Appoints Yong Ben as Chief Medical Officer
May 09, 2017 at 06:00 am EDT
Share
BioAtla, LLC announced the appointment of Yong Ben, M.D., as chief medical officer. Dr. Ben, an experienced biotechnology drug developer in oncology, joins the Company from AstraZeneca, where he was most recently Global Clinical Lead, Immuno-Oncology. His clinical leadership in pharmaceutical and biotechnology companies led to several oncology drug approvals including, for AstraZeneca, the most recent approval of a PD-L1 antibody, durvalumab (Imfinzi), for the treatment of urothelial cancer, ixazomib (Ninlaro) in multiple myeloma for Millennium/Takeda, axitinib (Inlyta) in renal cancer for Pfizer, and oncolytic virus H101 in head and neck cancer for SunwayBio.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
BIOATLA, INC. 
